SAVA250103P19000
- 14.35
- 0.000.00%
Cassava Sciences Newsroom
Cassava Laying off One-third of Staff to Curb Expenses
Express News | Cassava- Topline Data From Phase 3 Refocus-Alz Study of Simufilam in Patients With Mild-to-Moderate Alzheimer's Disease Expected Late Q1/Early Q2 2025
Express News | Cassava Sciences Inc: In Final Stages of Discontinuing Refocus-Alz Study
Express News | Cassava Sciences Inc: Implementing Cost Curtailment Including a Workforce Reduction of Approximately 33%
Express News | Cassava Sciences Provides a Business Update
Most Shorted Stocks on Wall Street Heading Into 2025: BYND, KSS, GRPN, and More
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
10 Health Care Stocks With Whale Alerts In Today's Session
A Post-Mortem on Cassava Sciences
Unpacking the Latest Options Trading Trends in Cassava Sciences
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
What's Left in Cassava After Phase 3 Setback for Alzheimer's Drug
Express News | Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences Analyst Ratings
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline
H.C. Wainwright Downgrades Cassava Sciences(SAVA.US) to Hold Rating
Express News | Cassava Sciences, Inc. : H.c. Wainwright Cuts to Neutral From Buy